The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

Because of the near-simultaneous approval of new metastatic RCC therapies that act on VEGF and the HIF transcription cascade, Trx inhibitors such as MGd should be explored as potential candidates ...

The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of people with metastatic NSCLC have a life expectancy of under 3 months.

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint inhibitor–refractory patients with NSCLC. Patients with advanced non–small cell lung ...

Isolation and Identification of Compounds from Bioactive Extracts of Taraxacum officinale Weber ex F. H. Wigg. (Dandelion) as a Potential Source of Antibacterial Agents.

S.W. Chung and J.S. Kim equally contributed to this article as co-first authors. W.-M. Choi and K.M. Kim equally contributed to this article as co-corresponding authors.